DexCom, Inc. (DXCM) EV/Assets Ratio: 4.49x
Is DexCom, Inc.’s EV/Assets ratio high or low?
DexCom, Inc.'s EV/Assets ratio of 4.49x is 40% below its 5-year average of 7.46x, near the low end of its 5-year range (3.08x–14.76x).
As of Thursday, June 11, 2026. 6.28% above its 12-month average of 4.22x.
DXCM EV/Assets Ratio Chart
DXCM Average EV/Assets Ratio Chart
DXCM Current vs Average EV/Assets Ratio Chart
DXCM EV/Assets Ratio Metrics
EV/ASSETS RATIO
4.49x
EV/ASSETS RATIO AVG TTM
4.22x
EV/ASSETS RATIO AVG 3Y
5.88x
EV/ASSETS RATIO AVG 5Y
7.46x
EV/ASSETS RATIO AVG 10Y
9.23x
EV/ASSETS RATIO AVG 15Y
11.99x
EV/ASSETS RATIO AVG 20Y
10.48x
CURRENT VS TTM AVG
+6.28%
CURRENT VS 3Y AVG
-23.64%
CURRENT VS 5Y AVG
-39.82%
CURRENT VS 10Y AVG
-51.36%
CURRENT VS 15Y AVG
-62.54%
CURRENT VS 20Y AVG
-57.15%
DXCM Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $28.92B | 4.49x | 4.22x | 5.88x | 7.46x |
| Biogen Inc. (BIIB) | $28.94B | 1.09x | 0.95x | 1.19x | 1.43x |
| IQVIA Holdings Inc. (IQV) | $30.08B | 1.04x | 1.56x | 1.81x | 1.98x |
| Medline Inc. (MDLN) | $31.40B | 1.05x | 1.17x | 1.17x | 1.17x |
| Veeva Systems Inc. (VEEV) | $26.31B | 2.78x | 4.63x | 5.33x | 6.99x |
| Centene Corporation (CNC) | $32.26B | 0.34x | 0.25x | 0.39x | 0.51x |
| Zoetis Inc. (ZTS) | $34.27B | 2.76x | 4.25x | 5.43x | 5.83x |
| Waters Corporation (WAT) | $23.21B | 1.42x | 4.12x | 4.55x | 5.47x |
| United Therapeutics Corporation (UTHR) | $23.15B | 3.67x | 2.68x | 2.17x | 2.06x |
| Mettler-Toledo International Inc. (MTD) | $22.82B | 6.83x | 8.26x | 8.63x | 9.33x |
DexCom, Inc. EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. EV/Assets Ratio FAQ
- What is the EV/Assets ratio for DexCom, Inc. (DXCM)?
- The EV/Assets ratio for DXCM stock is 4.49x.
- Is DexCom, Inc.'s EV/Assets ratio high or low?
- DexCom, Inc.'s EV/Assets ratio of 4.49x is 40% below its 5-year average of 7.46x, near the low end of its 5-year range (3.08x–14.76x).
- What is the TTM average EV/Assets ratio for DexCom, Inc. (DXCM)?
- The TTM average EV/Assets ratio for DXCM stock is 4.22x.
- What is the 3Y average EV/Assets ratio for DexCom, Inc. (DXCM)?
- The 3Y average EV/Assets ratio for DXCM stock is 5.88x.
- What is the 5Y average EV/Assets ratio for DexCom, Inc. (DXCM)?
- The 5Y average EV/Assets ratio for DXCM stock is 7.46x.
- What is the 10Y average EV/Assets ratio for DexCom, Inc. (DXCM)?
- The 10Y average EV/Assets ratio for DXCM stock is 9.23x.
- What is the 15Y average EV/Assets ratio for DexCom, Inc. (DXCM)?
- The 15Y average EV/Assets ratio for DXCM stock is 11.99x.
- What is the 20Y average EV/Assets ratio for DexCom, Inc. (DXCM)?
- The 20Y average EV/Assets ratio for DXCM stock is 10.48x.
DexCom, Inc. EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-11 | 4.49x |
| 2026-06-10 | 4.48x |
| 2026-06-09 | 4.68x |
| 2026-06-08 | 4.59x |
| 2026-06-05 | 4.36x |
| 2026-06-04 | 4.35x |
| 2026-06-03 | 4.36x |
| 2026-06-02 | 4.40x |
| 2026-06-01 | 4.48x |
| 2026-05-29 | 4.42x |
| 2026-05-28 | 4.33x |
| 2026-05-27 | 4.21x |
| 2026-05-26 | 4.31x |
| 2026-05-22 | 4.32x |
| 2026-05-21 | 4.31x |
| 2026-05-20 | 4.28x |
| 2026-05-19 | 4.01x |
| 2026-05-18 | 3.90x |
| 2026-05-15 | 3.70x |
| 2026-05-14 | 3.47x |
| 2026-05-13 | 3.52x |
| 2026-05-12 | 3.67x |
| 2026-05-11 | 3.56x |
| 2026-05-08 | 3.64x |
| 2026-05-07 | 3.65x |
| 2026-05-06 | 3.62x |
| 2026-05-05 | 3.57x |
| 2026-05-04 | 3.60x |
| 2026-05-01 | 3.68x |
| 2026-04-30 | 3.57x |
| 2026-04-29 | 3.70x |
| 2026-04-28 | 3.81x |
| 2026-04-27 | 3.94x |
| 2026-04-24 | 3.95x |
| 2026-04-23 | 4.02x |
| 2026-04-22 | 4.06x |
| 2026-04-21 | 4.01x |
| 2026-04-20 | 4.14x |
| 2026-04-17 | 4.10x |
| 2026-04-16 | 3.93x |
| 2026-04-15 | 3.95x |
| 2026-04-14 | 4.04x |
| 2026-04-13 | 4.05x |
| 2026-04-10 | 4.10x |
| 2026-04-09 | 4.21x |
| 2026-04-08 | 4.21x |
| 2026-04-07 | 4.05x |
| 2026-04-06 | 4.05x |
| 2026-04-02 | 3.99x |
| 2026-04-01 | 4.00x |
| 2026-03-31 | 4.03x |
| 2026-03-30 | 3.97x |
| 2026-03-27 | 3.99x |
| 2026-03-26 | 4.23x |
| 2026-03-25 | 4.28x |
| 2026-03-24 | 4.26x |
| 2026-03-23 | 4.22x |
| 2026-03-20 | 4.29x |
| 2026-03-19 | 4.31x |
| 2026-03-18 | 4.33x |
| 2026-03-17 | 4.31x |
| 2026-03-16 | 4.25x |
| 2026-03-13 | 4.12x |
| 2026-03-12 | 4.18x |
| 2026-03-11 | 4.25x |
| 2026-03-10 | 4.34x |
| 2026-03-09 | 4.40x |
| 2026-03-06 | 4.36x |
| 2026-03-05 | 4.52x |
| 2026-03-04 | 4.66x |
| 2026-03-03 | 4.67x |
| 2026-03-02 | 4.72x |
| 2026-02-27 | 4.69x |
| 2026-02-26 | 4.75x |
| 2026-02-25 | 4.68x |
| 2026-02-24 | 4.67x |
| 2026-02-23 | 4.68x |
| 2026-02-20 | 4.67x |
| 2026-02-19 | 4.62x |
| 2026-02-18 | 4.65x |
| 2026-02-17 | 4.51x |
| 2026-02-13 | 4.48x |
| 2026-02-12 | 4.17x |
| 2026-02-11 | 3.80x |
| 2026-02-10 | 3.80x |
| 2026-02-09 | 3.91x |
| 2026-02-06 | 3.90x |
| 2026-02-05 | 3.90x |
| 2026-02-04 | 3.95x |
| 2026-02-03 | 3.99x |
| 2026-02-02 | 4.04x |
| 2026-01-30 | 4.07x |
| 2026-01-29 | 4.12x |
| 2026-01-28 | 4.08x |
| 2026-01-27 | 4.10x |
| 2026-01-26 | 4.08x |
| 2026-01-23 | 4.06x |
| 2026-01-22 | 4.11x |
| 2026-01-21 | 4.02x |
| 2026-01-20 | 3.94x |
| 2026-01-16 | 3.88x |
| 2026-01-15 | 3.86x |
| 2026-01-14 | 3.88x |
| 2026-01-13 | 3.91x |
| 2026-01-12 | 3.95x |
| 2026-01-09 | 3.76x |
| 2026-01-08 | 3.82x |
| 2026-01-07 | 3.91x |
| 2026-01-06 | 3.90x |
| 2026-01-05 | 3.77x |
| 2026-01-02 | 3.71x |
| 2025-12-31 | 3.70x |
| 2025-12-30 | 3.74x |
| 2025-12-29 | 3.76x |
| 2025-12-26 | 3.77x |
| 2025-12-24 | 3.76x |
| 2025-12-23 | 3.73x |
| 2025-12-22 | 3.76x |
| 2025-12-19 | 3.69x |
| 2025-12-18 | 3.68x |
| 2025-12-17 | 3.67x |
| 2025-12-16 | 3.70x |
| 2025-12-15 | 3.67x |
| 2025-12-12 | 3.74x |
| 2025-12-11 | 3.84x |
| 2025-12-10 | 3.77x |
| 2025-12-09 | 3.70x |
| 2025-12-08 | 3.66x |
| 2025-12-05 | 3.66x |
| 2025-12-04 | 3.64x |
| 2025-12-03 | 3.62x |
| 2025-12-02 | 3.60x |
| 2025-12-01 | 3.55x |
| 2025-11-28 | 3.55x |
| 2025-11-26 | 3.50x |
| 2025-11-25 | 3.45x |
| 2025-11-24 | 3.48x |
| 2025-11-21 | 3.37x |
| 2025-11-20 | 3.27x |
| 2025-11-19 | 3.34x |
| 2025-11-18 | 3.37x |
| 2025-11-17 | 3.28x |
| 2025-11-14 | 3.25x |
| 2025-11-13 | 3.34x |
| 2025-11-12 | 3.34x |
| 2025-11-11 | 3.26x |
| 2025-11-10 | 3.08x |
| 2025-11-07 | 3.09x |
| 2025-11-06 | 3.25x |
| 2025-11-05 | 3.32x |
| 2025-11-04 | 3.42x |
| 2025-11-03 | 3.38x |
| 2025-10-31 | 3.26x |
| 2025-10-30 | 3.80x |
| 2025-10-29 | 3.99x |
| 2025-10-28 | 4.05x |
| 2025-10-27 | 4.13x |
| 2025-10-24 | 4.11x |
| 2025-10-23 | 4.15x |
| 2025-10-22 | 4.13x |
| 2025-10-21 | 4.08x |
| 2025-10-20 | 4.01x |
| 2025-10-17 | 3.90x |
| 2025-10-16 | 3.89x |
| 2025-10-15 | 3.84x |
| 2025-10-14 | 3.88x |
| 2025-10-13 | 3.83x |
| 2025-10-10 | 3.82x |
| 2025-10-09 | 3.99x |
| 2025-10-08 | 3.97x |
| 2025-10-07 | 3.87x |
| 2025-10-06 | 3.89x |
| 2025-10-03 | 3.93x |
| 2025-10-02 | 3.90x |
| 2025-10-01 | 3.88x |
| 2025-09-30 | 3.94x |
| 2025-09-29 | 3.90x |
| 2025-09-26 | 3.93x |
| 2025-09-25 | 4.00x |
| 2025-09-24 | 3.95x |
| 2025-09-23 | 3.99x |
| 2025-09-22 | 4.07x |
| 2025-09-19 | 3.95x |
| 2025-09-18 | 4.42x |
| 2025-09-17 | 4.45x |
| 2025-09-16 | 4.46x |
| 2025-09-15 | 4.40x |
| 2025-09-12 | 4.44x |
| 2025-09-11 | 4.43x |
| 2025-09-10 | 4.43x |
| 2025-09-09 | 4.56x |
| 2025-09-08 | 4.54x |
| 2025-09-05 | 4.68x |
| 2025-09-04 | 4.69x |
| 2025-09-03 | 4.59x |
| 2025-09-02 | 4.33x |
| 2025-08-29 | 4.39x |
| 2025-08-28 | 4.38x |
| 2025-08-27 | 4.45x |
| 2025-08-26 | 4.43x |
| 2025-08-25 | 4.43x |
| 2025-08-22 | 4.78x |
| 2025-08-21 | 4.69x |
| 2025-08-20 | 4.74x |
| 2025-08-19 | 4.70x |
| 2025-08-18 | 4.70x |
| 2025-08-15 | 4.70x |
| 2025-08-14 | 4.65x |
| 2025-08-13 | 4.65x |
| 2025-08-12 | 4.66x |
| 2025-08-11 | 4.53x |
| 2025-08-08 | 4.59x |
| 2025-08-07 | 4.45x |
| 2025-08-06 | 4.45x |
| 2025-08-05 | 4.40x |
| 2025-08-04 | 4.44x |
| 2025-08-01 | 4.61x |
| 2025-07-31 | 4.69x |
| 2025-07-30 | 5.16x |
| 2025-07-29 | 5.64x |
| 2025-07-28 | 5.65x |
| 2025-07-25 | 5.62x |
| 2025-07-24 | 5.48x |
| 2025-07-23 | 5.47x |
| 2025-07-22 | 5.39x |
| 2025-07-21 | 5.32x |
| 2025-07-18 | 5.31x |
| 2025-07-17 | 5.32x |
| 2025-07-16 | 5.33x |
| 2025-07-15 | 5.37x |
| 2025-07-14 | 5.40x |
| 2025-07-11 | 5.28x |
| 2025-07-10 | 5.41x |
| 2025-07-09 | 5.37x |
| 2025-07-08 | 5.30x |
| 2025-07-07 | 5.25x |
| 2025-07-03 | 5.25x |
| 2025-07-02 | 5.29x |
| 2025-07-01 | 5.29x |
| 2025-06-30 | 5.52x |
| 2025-06-27 | 5.46x |
| 2025-06-26 | 5.38x |
| 2025-06-25 | 5.36x |
| 2025-06-24 | 5.53x |
| 2025-06-23 | 5.07x |
| 2025-06-20 | 5.08x |
| 2025-06-18 | 5.14x |
| 2025-06-17 | 5.19x |
| 2025-06-16 | 5.26x |
| 2025-06-13 | 5.20x |
| 2025-06-12 | 5.25x |
| 2025-06-11 | 5.26x |
| 2025-06-10 | 5.37x |
| 2025-06-09 | 5.42x |
| 2025-06-06 | 5.48x |
| 2025-06-05 | 5.42x |
| 2025-06-04 | 5.42x |
| 2025-06-03 | 5.49x |
| 2025-06-02 | 5.41x |
| 2025-05-30 | 5.43x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach